Abstract
We investigated what information women diagnosed with breast cancer at a young age would want to learn when genome sequencing results are returned. We conducted 60 semi-structured interviews with women diagnosed with breast cancer at age 40 or younger. We examined what specific information participants would want to learn across result types and for each type of result, as well as how much information they would want. Genome sequencing was not offered to participants as part of the study. Two coders independently coded interview transcripts; analysis was conducted using NVivo10. Across result types, participants wanted to learn about health implications, risk and prevalence in quantitative terms, causes of variants, and causes of diseases. Participants wanted to learn actionable information for variants affecting risk of preventable or treatable disease, medication response, and carrier status. The amount of desired information differed for variants affecting risk of unpreventable or untreatable disease, with uncertain significance, and not health-related. Women diagnosed with breast cancer at a young age recognize the value of genome sequencing results in identifying potential causes and effective treatments and expressed interest in using the information to help relatives and to further understand their other health risks. Our findings can inform the development of effective feedback strategies for genome sequencing that meet patients’ information needs and preferences.
References
Anders, C. K., Hsu, D. S., Broadwater, G., Acharya, C. R., Foekens, J. A., Zhang, Y., et al. (2008). Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. Journal of Clinical Oncology, 26(20), 3324–3330. doi:10.1200/jco.2007.14.2471.
Anders, C. K., Johnson, R., Litton, J., Phillips, M., & Bleyer, A. (2009). Breast cancer before age 40 years. Seminars in Oncology, 36(3), 237–249. doi:10.1053/j.seminoncol.2009.03.001.
Assi, H. A., Khoury, K. E., Dbouk, H., Khalil, L. E., Mouhieddine, T. H., & El Saghir, N. S. (2013). Epidemiology and prognosis of breast cancer in young women. Journal of Thoracic Disease, 5(Suppl 1), S2–S8. doi:10.3978/j.issn.2072-1439.2013.05.24.
Biesecker, L. G., & Green, R. C. (2014). Diagnostic clinical genome and exome sequencing. The New England Journal of Medicine, 370(25), 2418–2425. doi:10.1056/NEJMra1312543.
Bonadona, V., Sinilnikova, O. M., Chopin, S., Antoniou, A. C., Mignotte, H., Mathevet, P., et al. (2005). Contribution of BRCA1 and BRCA2 germ-line mutations to the incidence of breast cancer in young women: results from a prospective population-based study in France. Genes, Chromosomes & Cancer, 43(4), 404–413. doi:10.1002/gcc.20199.
Bredenoord, A. L., Kroes, H. Y., Cuppen, E., Parker, M., & van Delden, J. J. (2011). Disclosure of individual genetic data to research participants: the debate reconsidered. Trends in Genetics, 27(2), 41–47. doi:10.1016/j.tig.2010.11.004.
Caulfield, T., McGuire, A. L., Cho, M., Buchanan, J. A., Burgess, M. M., Danilczyk, U., et al. (2008). Research ethics recommendations for whole-genome research: consensus statement. PLoS Biology, 6(3), e73. doi:10.1371/journal.pbio.0060073.
Christenhusz, G. M., Devriendt, K., Peeters, H., Van Esch, H., & Dierickx, K. (2014). The communication of secondary variants: interviews with parents whose children have undergone array-CGH testing. Clinical Genetics, 86(3), 207–216. doi:10.1111/cge.12354.
Crouch, J., Yu, J. H., Shankar, A. G., & Tabor, H. K. (2015). “We don’t know her history, her background”: adoptive parents’ perspectives on whole genome sequencing results. Journal of Genetic Counseling, 24(1), 67–77. doi:10.1007/s10897-014-9738-z.
Cybulski, C., Wokolorczyk, D., Jakubowska, A., Huzarski, T., Byrski, T., Gronwald, J., et al. (2011). Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer. Journal of Clinical Oncology, 29(28), 3747–3752. doi:10.1200/jco.2010.34.0778.
Desmond, A., Kurian, A. W., Gabree, M., Mills, M. A., Anderson, M. J., Kobayashi, Y., et al. (2015). Clinical actionability of multigene panel testing for hereditary breast and ovarian cancer risk assessment. JAMA Oncology, 1(7), 943–951. doi:10.1001/jamaoncol.2015.2690.
Dressler, L. G. (2009a). Biobanking and disclosure of research results: Addressing the tension between professional boundaries and moral intuition. In J. H. Solbakk, S. Holm, & B. Hofmann (Eds.), The ethics of research biobanking (pp. 85–99). New York: Springer.
Dressler, L. G. (2009b). Disclosure of research results from cancer genomic studies: state of the science. Clinical Cancer Research, 15(13), 4270–4276. doi:10.1158/1078-0432.CCR-08-3067.
Ellis, M. J., Ding, L., Shen, D., Luo, J., Suman, V. J., Wallis, J. W., & Mardis, E. R. (2012). Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature, 486(7403), 353–360. doi:10.1038/nature11143.
Facio, F. M., Brooks, S., Loewenstein, J., Green, S., Biesecker, L. G., & Biesecker, B. B. (2011). Motivators for participation in a whole-genome sequencing study: implications for translational genomics research. European Journal of Human Genetics, 19(12), 1213–1217. doi:10.1038/ejhg.2011.123.
Fredholm, H., Eaker, S., Frisell, J., Holmberg, L., Fredriksson, I., & Lindman, H. (2009). Breast cancer in young women: poor survival despite intensive treatment. PloS One, 4(11), e7695. doi:10.1371/journal.pone.0007695.
Golshan, M., Miron, A., Nixon, A. J., Garber, J. E., Cash, E. P., Iglehart, J. D., & Wong, J. S. (2006). The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. American Journal of Surgery, 192(1), 58–62. doi:10.1016/j.amjsurg.2005.12.005.
Gray, S. W., Hicks-Courant, K., Cronin, A., Rollins, B. J., & Weeks, J. C. (2014). Physicians’ attitudes about multiplex tumor genomic testing. Journal of Clinical Oncology, 32(13), 1317–1323. doi:10.1200/JCO.2013.52.4298.
Green, R. C., Berg, J. S., Grody, W. W., Kalia, S. S., Korf, B. R., Martin, C. L., & Genomics (2013). ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genetics in Medicine, 15(7), 565–574. doi:10.1038/gim.2013.73.
Green, R. C., Goddard, K. A., Jarvik, G. P., Amendola, L. M., Appelbaum, P. S., Berg, J. S., et al. (2016). Clinical sequencing exploratory research consortium: accelerating evidence-based practice of genomic medicine. American Journal of Human Genetics, 98(6), 1051–1066. doi:10.1016/j.ajhg.2016.04.011.
Guba, E. G., & Lincoln, Y. S. (1994). Competing paradigms in qualitative research. In N. K. Denzin & Y. S. Lincoln (Eds.), Handbook of qualitative research (pp. 105–117). Thousand Oaks: Sage.
Heemskerk-Gerritsen, B. A., Rookus, M. A., Aalfs, C. M., Ausems, M. G., Collee, J. M., Jansen, L., et al. (2015). Improved overall survival after contralateral risk-reducing mastectomy in BRCA1/2 mutation carriers with a history of unilateral breast cancer: a prospective analysis. International Journal of Cancer, 136(3), 668–677. doi:10.1002/ijc.29032.
Hitch, K., Joseph, G., Guiltinan, J., Kianmahd, J., Youngblom, J., & Blanco, A. (2014). Lynch syndrome patients’ views of and preferences for return of results following whole exome sequencing. Journal of Genetic Counseling, 23(4), 539–551. doi:10.1007/s10897-014-9687-6.
Hsieh, H. F., & Shannon, S. E. (2005). Three approaches to qualitative content analysis. Qualitative Health Research, 15(9), 1277–1288. doi:10.1177/1049732305276687.
Ingham, S. L., Sperrin, M., Baildam, A., Ross, G. L., Clayton, R., Lalloo, F., et al. (2013). Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral. Breast Cancer Research and Treatment, 142(3), 611–618. doi:10.1007/s10549-013-2765-x.
Institute of Medicine (2001). Crossing the quality chasm: A new health system for the 21st century. Washington, D.C.: National Academies Press.
Jamal, S. M., Yu, J. H., Chong, J. X., Dent, K. M., Conta, J. H., Tabor, H. K., & Bamshad, M. J. (2013). Practices and policies of clinical exome sequencing providers: analysis and implications. American Journal of Medical Genetics. Part A, 161A(5), 935–950. doi:10.1002/ajmg.a.35942.
Janatova, M., Kleibl, Z., Stribrna, J., Panczak, A., Vesela, K., Zimovjanova, M., et al. (2013). The PALB2 gene is a strong candidate for clinical testing in BRCA1- and BRCA2-negative hereditary breast cancer. Cancer Epidemiology, Biomarkers & Prevention, 22(12), 2323–2332. doi:10.1158/1055-9965.epi-13-0745-t.
Johnson, R. H., Chien, F. L., & Bleyer, A. (2013). Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA, 309(8), 800–805. doi:10.1001/jama.2013.776.
Kaphingst, K. A., McBride, C. M., Wade, C., Alford, S. H., Brody, L. C., & Baxevanis, A. D. (2010). Consumers’ use of web-based information and their decisions about multiplex genetic susceptibility testing. Journal of Medical Internet Research, 12(3), e41. doi:10.2196/jmir.1587.
Kaphingst, K. A., Ivanovich, J., Biesecker, B. B., Dresser, R., Seo, J., Dressler, L. G., & Goodman, M. S. (2016). Preferences for return of incidental findings from genome sequencing among women diagnosed with breast cancer at a young Age. Clinical Genetics, 89(3), 378–384. doi:10.1111/cge.12597.
Leventhal, K. G., Tuong, W., Peshkin, B. N., Salehizadeh, Y., Fishman, M. B., Eggly, S., et al. (2013). “Is it really worth it to get tested?”: primary care patients’ impressions of predictive SNP testing for colon cancer. Journal of Genetic Counseling, 22(1), 138–151. doi:10.1007/s10897-012-9530-x.
Manolio, T. A., Chisholm, R. L., Ozenberger, B., Roden, D. M., Williams, M. S., Wilson, R., et al. (2013). Implementing genomic medicine in the clinic: the future is here. Genetics in Medicine, 15(4), 258–267. doi:10.1038/gim.2012.157.
Mardis, E. R. (2008). The impact of next-generation sequencing technology on genetics. Trends in Genetics, 24(3), 133–141. doi:10.1016/j.tig.2007.12.007.
Matsui, K., Lie, R. K., Kita, Y., & Ueshima, H. (2008). Ethics of future disclosure of individual risk information in a genetic cohort study: a survey of donor preferences. Journal of Epidemiology, 18(5), 217–224.
Mavaddat, N., Peock, S., Frost, D., Ellis, S., Platte, R., Fineberg, E., et al. (2013). Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. Journal of the National Cancer Institute, 105(11), 812–822. doi:10.1093/jnci/djt095.
McGuire, A. L., & Lupski, J. R. (2010). Personal genome research : what should the participant be told? Trends in Genetics, 26(5), 199–201. doi:10.1016/j.tig.2009.12.007.
McLaughlin, H. M., Ceyhan-Birsoy, O., Christensen, K. D., Kohane, I. S., Krier, J., Lane, W. J., & MedSeq, P. (2014). A systematic approach to the reporting of medically relevant findings from whole genome sequencing. BMC Medical Genetics, 15, 134. doi:10.1186/s12881-014-0134-1.
Murphy, J., Scott, J., Kaufman, D., Geller, G., LeRoy, L., & Hudson, K. (2008). Public expectations for return of results from large-cohort genetic research. The American Journal of Bioethics, 8(11), 36–43. doi:10.1080/15265160802513093.
O’Daniel, J., & Haga, S. B. (2011). Public perspectives on returning genetics and genomics research results. Public Health Genomics, 14, 346–355. doi:10.1159/000324933.
O’Neill, S. C., Lipkus, I. M., Sanderson, S. C., Shepperd, J., Docherty, S., & McBride, C. M. (2013). Motivations for genetic testing for lung cancer risk among young smokers. Tobacco Control, 22(6), 406–411. doi:10.1136/tobaccocontrol-2011-050306.
Pasche, B., & Absher, D. (2011). Whole-genome sequencing: a step closer to personalized medicine. JAMA, 305(15), 1596–1597. doi:10.1001/jama.2011.484.
Renwick, A., Thompson, D., Seal, S., Kelly, P., Chagtai, T., Ahmed, M., et al. (2006). ATM mutations that cause ataxia-telangiectasia are breast cancer susceptibility alleles. Nature Genetics, 38(8), 873–875. doi:10.1038/ng1837.
Riedl, C. C., Slobod, E., Jochelson, M., Morrow, M., Goldman, D. A., Gonen, M., & Ulaner, G. A. (2014). Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years. Journal of Nuclear Medicine, 55(10), 1578–1583. doi:10.2967/jnumed.114.143297.
Rutten, L. J., Arora, N. K., Bakos, A. D., Aziz, N., & Rowland, J. (2005). Information needs and sources of information among cancer patients: a systematic review of research (1980–2003). Patient Education and Counseling, 57(3), 250–261. doi:10.1016/j.pec.2004.06.006.
Schmidlen, T. J., Wawak, L., Kasper, R., Garcia-Espana, J. F., Christman, M. F., & Gordon, E. S. (2014). Personalized genomic results: analysis of informational needs. Journal of Genetic Counseling, 23(4), 578–587. doi:10.1007/s10897-014-9693-8.
Selkirk, C. G., Weissman, S. M., Anderson, A., & Hulick, P. J. (2013). Physicians’ preparedness for integration of genomic and pharmacogenetic testing into practice within a major healthcare system. Genetic Testing and Molecular Biomarkers, 17(3), 219–225. doi:10.1089/gtmb.2012.0165.
Sharp, R. R. (2011). Downsizing genomic medicine: approaching the ethical complexity of whole-genome sequencing by starting small. Genetics in Medicine, 13(3), 191–194. doi:10.1097/GIM.0b013e31820f603f.
Sieh, W., Rothstein, J. H., McGuire, V., & Whittemore, A. S. (2014). The role of genome sequencing in personalized breast cancer prevention. Cancer Epidemiology, Biomarkers & Prevention, 23(11), 2322–2327. doi:10.1158/1055-9965.epi-14-0559.
Tabor, H. K., Stock, J., Brazg, T., McMillin, M. J., Dent, K. M., Yu, J. H., et al. (2012). Informed consent for whole genome sequencing: a qualitative analysis of participant expectations and perceptions of risks, benefits, and harms. American Journal of Medical Genetics. Part A, 158A(6), 1310–1319. doi:10.1002/ajmg.a.35328.
Taplin, S. H., Anhang Price, R., Edwards, H. M., Foster, M. K., Breslau, E. S., Chollette, V., et al. (2012). Introduction: Understanding and influencing multilevel factors across the cancer care continuum. Journal of the National Cancer Institute. Monographs, 2012(44), 2–10. doi:10.1093/jncimonographs/lgs008.
Trujillano, D., Weiss, M. E., Schneider, J., Koster, J., Papachristos, E. B., Saviouk, V., et al. (2015). Next-generation sequencing of the BRCA1 and BRCA2 genes for the genetic diagnostics of hereditary breast and/or ovarian cancer. The Journal of Molecular Diagnostics, 17(2), 162–170. doi:10.1016/j.jmoldx.2014.11.004.
Wright, M. F., Lewis, K. L., Fisher, T. C., Hooker, G. W., Emanuel, T. E., Biesecker, L. G., & Biesecker, B. B. (2014). Preferences for results delivery from exome sequencing/genome sequencing. Genetics in Medicine, 16(6), 442–447. doi:10.1038/gim.2013.170.
Yauch, R. L., & Settleman, J. (2012). Recent advances in pathway-targeted cancer drug therapies emerging from cancer genome analysis. Current Opinion in Genetics & Development, 22(1), 45–49. doi:10.1016/j.gde.2012.01.003.
Yu, J. H., Crouch, J., Jamal, S. M., Bamshad, M. J., & Tabor, H. K. (2014). Attitudes of non-African American focus group participants toward return of results from exome and whole genome sequencing. American Journal of Medical Genetics. Part A, 164A(9), 2153–2160. doi:10.1002/ajmg.a.36610.
Zardavas, D., Baselga, J., & Piccart, M. (2013). Emerging targeted agents in metastatic breast cancer. Nature Reviews. Clinical Oncology, 10(4), 191–210. doi:10.1038/nrclinonc.2013.29.
Acknowledgments
This work was supported by the National Cancer Institute, National Institutes of Health (R01CA168608). This research was also supported in part by the Intramural Research Program of the National Human Genome Research Institute, National Institutes of Health.
The authors would like to thank the women who agreed to participate in the study, and the coders for their valuable assistance in coding interview transcripts.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
Joann Seo, Jennifer Ivanovich, Melody Goodman, Barbara Biesecker, and Kimberly Kaphingst declare that they have no conflict of interest.
Human Studies and Informed Consent
All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained from all patients for being included in the study.
Animal Studies
No animal studies were carried out by the authors for this article.
Rights and permissions
About this article
Cite this article
Seo, J., Ivanovich, J., Goodman, M.S. et al. Information Topics of Greatest Interest for Return of Genome Sequencing Results among Women Diagnosed with Breast Cancer at a Young Age. J Genet Counsel 26, 511–521 (2017). https://doi.org/10.1007/s10897-016-0006-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10897-016-0006-2